When planning a growth hormone secretagogue protocol, one of the biggest debates often comes down to cost versus targeted results—specifically around visceral fat reduction. Tesamorelin is widely recognized as the gold standard in clinical literature because it is specifically FDA-approved and backed by solid human clinical trials demonstrating a significant reduction in deep visceral adipose tissue. Other GHRH analogs (like CJC-1295 / Mod GRF 1-29) stimulate endogenous GH release and theoretically aid lipolysis, but they lack the same extensive, dedicated human trial data specifically measuring visceral fat loss. The trade-off, however, shows up quickly in the pricing: - CJC-1295 (No DAC) + Ipamorelin Blend (5mg / 5mg): ~$89.29 per kit (plus shipping & fees) - Tesamorelin + Ipamorelin Blend (10mg / 5mg): ~$242.00 per kit (plus shipping & fees) That is a fairly significant price spread. For general body composition, recovery, sleep, and overall GH elevation, the CJC/Ipamorelin route offers a much lower cost of entry. But for research focused specifically on stubborn visceral fat where human data matters most, Tesamorelin remains the primary compound with clinical proof behind that specific mechanism. What has been your experience? For those who have run both, did the visceral fat results from Tesamorelin justify the higher price tag over standard CJC-1295/Ipamorelin blends?

Does anyone know of a reputable supplier for pe-22-28?

Does anyone know if there’s an equivalent peptide to this?

Is it possible to take Injectable SLU as sublingual? its hard to come by Sublingual tabs. Tried both local suppliers and even over the seas. Why sublingual? More Bioavailability!

As part of our commitment to transparency, I like to keep everyone informed about important developments within the industry. Recently, a number of rumors have been circulating that have created unnecessary concern. Please take a moment to read this entire message for clarity and accurate context. Industry Update Over the past year, several large companies—some owned by high-profile influencers—have entered the market. These companies have been openly selling RUO (Research Use Only) products while simultaneously promoting or implying human use, and in some cases marketing to practitioners under separate entities. Many of these companies sponsor major biohacking, anti-aging, and peptide conferences and actively solicit business from doctors and clinics. At the most recent A4M conference, rumors began circulating—originating from some of these same companies—suggesting they were discontinuing GLP products and claiming that government agencies would soon begin shutting down RUO companies altogether. To date, these claims remain unsubstantiated. Notably, many of these rumors trace back to one of the largest peptide influencers, who continues to openly discuss human use. This is a practice we are firmly opposed to at Step One and do not promote in any capacity. To be clear: these are rumors only. That said, we are seeing ripple effects overseas. One of our manufacturing partners has temporarily paused its peptide division, citing increased scrutiny driven by unlicensed operations and irresponsible promotion on social media. They expressed concern that poorly manufactured, untested, or counterfeit products—often tied to unknown labs—have drawn unwanted attention to the industry as a whole, including legitimate manufacturers. Our Position & Holiday Plans Despite the noise, S1Research.net remains fully operational and on track. We are proceeding exactly as planned with the holiday promotions announced last week, and we have multiple large restocking orders already in transit.